Abstract
In 2015, as part of the Prostate Cancer Foundation–Movember Foundation Reproducibility Initiative, we published a Registered Report (Shan et al., 2015) that described how we intended to replicate selected experiments from the paper “Androgen Receptor Splice Variants Determine Taxane Sensitivity in Prostate Cancer” (Thadani-Mulero et al., 2014). Here we report the results of those experiments. Growth of tumor xenografts from two prostate cancer xenograft lines, LuCaP 86.2, which expresses wild-type androgen receptor (AR) and AR variant 567, and LuCaP 23.1, which expresses wild-type AR and AR variant 7, were not affected by docetaxel treatment. The LuCaP 23.1 tumor xenografts grew slower than in the original study. This result is different from the original study, which reported significant reduction of tumor growth in the LuCaP 86.2. Furthermore, we were unable to detect ARv7 in the LuCaP 23.1, although we used the antibody as stated in the original study and ensured that it was detecting ARv7 via a known positive control (22rv1, Hörnberg et al., 2011). Finally, we report a meta-analysis of the result.
Highlights
The Prostate Cancer Foundation–Movember Foundation Reproducibility Initiative is a collaboration between Science Exchange and the Prostate Cancer Foundation aiming to replicate key experimental results from high impact papers published in the prostate cancer field
They reported that docetaxel treatment reduced tumor growth significantly in tumors derived from LuCaP 86.2 cells, while tumors derived from LuCaP 23.1 did not show tumor growth reduction, suggesting that docetaxel affects the androgen receptor (AR) splice variants differently
AR variant expression profile of LuCaP 86.2 and LuCaP 23.1 prostate cancer cells In order to confirm the expression profile of the AR splice variants of each xenograft tissue, we performed western blot analysis of protein expression (Replication Fig. 1, https://osf.io/z3bva/, with raw data files found within the corresponding folder in https://osf.io/vdqcw/)
Summary
The Prostate Cancer Foundation–Movember Foundation Reproducibility Initiative is a collaboration between Science Exchange and the Prostate Cancer Foundation aiming to replicate key experimental results from high impact papers published in the prostate cancer field. Protocol 1: response of xenograft tumors derived from LuCaP 86.2 and LuCaP 23.1 prostate cancer cells to treatment with docetaxel
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
